0001787306-26-000040
SEC filingQ1 revenue surged 60% YoY to $105.4M on accelerating ZORYVE demand in the US and Canada launch, delivering positive free cash flow of $2.2M despite operating investments driving a narrowed net loss of $11.3M.
Gross profit reached $95.6 million, a 68% increase from $57.0 million, yielding an exceptional 90.7% margin. This stems from the accounting treatment where, subsequent to initial regulatory approval, production costs are capitalized into inventory; as inventory sells and revenue is recognized, those costs flow through cost of sales. The high margin underscores operational efficiency in scaling production to meet demand without proportional cost increases in the period.
Despite revenue acceleration, operating income remained negative at -$9.1 million, improved 63% from -$24.5 million last year, with an operating margin of -8.6%. The narrower loss highlights leverage from top-line growth, though tempered by necessary commercialization investments. Increases in sales and marketing expenses, along with compensation and employee benefits, supported ZORYVE's expansion but offset some profitability gains.
Net income loss narrowed to -$11.3 million from -$25.1 million, with diluted EPS at -$0.09 versus -$0.20, a 55% improvement. This progress demonstrates how revenue scale is beginning to absorb fixed and semi-variable costs, positioning the company for future margin expansion as volumes grow.
Cash flow marked a key inflection, with net cash from operating activities at $2.2 million versus a -$30.4 million outflow last year, and zero capital expenditures yielding positive free cash flow of $2.2 million. This shift arises from working capital gains tied to revenue growth and disciplined operations, providing liquidity to fund ongoing initiatives without dilution pressure.